دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Weekly Insulin Becoming a Reality
Jay S. Skyler
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1459-1461.
Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial
Noel T. Mueller, Moira K. Differding, Mingyu Zhang, Nisa M. Maruthur, Stephen P. Juraschek, Edgar R. Miller, Lawrence J. Appel and Hsin-Chieh Yeh
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1462-1471.
OBJECTIVE To determine the longer-term effects of metformin treatment and behavioral weight loss on gut microbiota and short-chain fatty acids (SCFAs).
Reductions in Management Distress Following a Randomized Distress Intervention Are Associated With Improved Diabetes Behavioral and Glycemic Outcomes Over Time
Danielle Hessler, Lisa Strycker and Lawrence Fisher
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1472-1479.
OBJECTIVE To explore associations between reductions in diabetes distress (DD) and improvements in glycemic outcomes among adults with type 1 diabetes (T1D) in the context of a DD randomized clinical trial.
Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes
Ashby F. Walker, Korey K. Hood, Matthew J. Gurka, Stephanie L. Filipp, Claudia Anez-Zabala, Nicolas Cuttriss, Michael J. Haller, Xanadu Roque, Diana Naranjo, Gina Aulisio, Ananta Addala, Jason Konopack, Sarah Westen, Katarina Yabut, Elvira Mercado, Sydney Look, Brian Fitzgerald, Jennifer Maizel and David M. Maahs
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1480-1490.
OBJECTIVE Disparities in type 1 diabetes related to use of technologies like continuous glucose monitors (CGMs) and utilization of diabetes care are pronounced based on socioeconomic status (SES), race, and ethnicity. However, systematic reports of perspectives from patients in vulnerable communities regarding barriers are limited.
Association of Psychobehavioral Variables With HOMA-IR and BMI Differs for Men and Women With Prediabetes in the PREVIEW Lifestyle Intervention
Tanja C. Adam, Mathijs Drummen, Ian Macdonald, Elli Jalo, Pia Siig-Vestentoft, J. Alfredo Martinez, Teodora Handjiev-Darlenska, Jennie Brand-Miller, Sally Poppitt, Gareth Stratton, Mikael Fogelholm, Kirsi H. Pietil?inen, Moira Taylor, Santiago Navas-Carretero, Bjorn Winkens, Svetoslav Handjiev, Roslyn Muirhead, Marta Silvestre, Nils Swindell, Maija Huttunen-Lenz, Wolfgang Schlicht, Tony Lam, Jouko Sundvall, Laura R?man, Edith Feskens, Thomas-Meinert Larssen, Angelo Tremblay, Anne Raben and Margriet Westerterp-Plantenga
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1491-1498.
OBJECTIVE Stress, sleep, eating behavior, and physical activity are associated with weight change and insulin resistance (IR). The aim of this analysis was the assessment of the overall and sex-specific associations of psychobehavioral variables throughout the 3-year PREVIEW intervention using the homeostatic model assessment of IR (HOMA-IR), BMI, and length of time in the study.
Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes
Rose Gubitosi-Klug, Xiaoyu Gao, Rodica Pop-Busui, Ian H. de Boer, Neill White, Lloyd P. Aiello, Ryan Miller, Jerry Palmer, William Tamborlane, Amisha Wallia, Mikhail Kosiborod, John M. Lachin, Ionut Bebu and the DCCT/EDIC Research Group
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1499-1505.
OBJECTIVE We examined whether the presence of microvascular complications was associated with increased subsequent risk of cardiovascular disease (CVD) among participants with type 1 diabetes in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study followed for >35 years.
Land Cover of Early-Life Environment Modulates the Risk of Type 1 Diabetes
Noora Nurminen, Damiano Cerrone, Jussi Lehtonen, Anirudra Parajuli, Marja Roslund, Maria L?nnrot, Jorma Ilonen, Jorma Toppari, Riitta Veijola, Mikael Knip, Juho Rajaniemi, Olli H. Laitinen, Aki Sinkkonen and Heikki Hy?ty
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1506-1514.
OBJECTIVE Environmental microbial exposures have been implicated to protect against immune-mediated diseases such as type 1 diabetes. Our objective was to study the association of land cover around the early-life dwelling with the development of islet autoimmunity and type 1 diabetes to evaluate the role of environmental microbial biodiversity in the pathogenesis.
Projecting the Incidence of Type 2 Diabetes–Related End-Stage Kidney Disease Until 2040: A Comparison Between the Effects of Diabetes Prevention and the Effects of Diabetes Treatment
Jedidiah I. Morton, Stephen P. McDonald, Agus Salim, Danny Liew, Jonathan E. Shaw and Dianna J. Magliano
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1515-1523.
OBJECTIVE This study sought to examine the effects of two diabetes prevention approaches and of widespread use of sodium–glucose cotransporter 2 inhibitors (SGLT2is) among people with diabetes on the future incidence of diabetes-related end-stage kidney disease (ESKD-D).
American Diabetes Association Framework for Glycemic Control in Older Adults: Implications for Risk of Hospitalization and Mortality
Mary R. Rooney, Olive Tang, Justin B. Echouffo Tcheugui, Pamela L. Lutsey, Morgan E. Grams, B. Gwen Windham and Elizabeth Selvin
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1524-1531.
OBJECTIVE The 2021 American Diabetes Association (ADA) guidelines recommend different A1C targets in older adults that are based on comorbid health status. We assessed risk of mortality and hospitalizations in older adults with diabetes across glycemic control (A1C <7%, 7 to <8%, ?8%) and ADA-defined health status (healthy, complex/intermediate, very complex/poor) categories.
The Effectiveness of a Proactive, Three-Level Strategy to Identify People With Prediabetes in a Large Workforce With Employer-Sponsored Health Insurance
William H. Herman, Kevin Joiner, Thomas Hurst and Laura N. McEwen
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1532-1539.
OBJECTIVE Rates of diagnosis of prediabetes and uptake of the National Diabetes Prevention Program (NDPP) are low. We evaluated a proactive three-level strategy to identify individuals with prediabetes in a population with employer-sponsored health insurance.
Frequency of Autoantibody-Negative Type 1 Diabetes in Children, Adolescents, and Young Adults During the First Wave of the COVID-19 Pandemic in Germany
Clemens Kamrath, Joachim Rosenbauer, Sascha R. Tittel, Katharina Warncke, Raphael Hirtz, Christian Denzer, Axel Dost, Andreas Neu, Danièle Pacaud and Reinhard W. Holl
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1540-1546.
OBJECTIVE The aim of this study was to investigate the frequency of newly diagnosed type 1 diabetes without evidence of autoimmunity and the respective frequencies of ketoacidosis in children, adolescents, and young adults during the coronavirus disease 2019 (COVID-19) pandemic in Germany compared with the previous decade.
Risk Factors for Incident Fracture in Older Adults With Type 2 Diabetes: The Framingham Heart Study
Alyssa B. Dufour, Douglas P. Kiel, Setareh A. Williams, Richard J. Weiss and Elizabeth J. Samelson
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1547-1555.
RESEARCH DESIGN AND METHODS This prospective study included members of the Framingham Original and Offspring Cohorts. Type 2 diabetes was defined as fasting plasma glucose >125 mg/dL or use of type 2 diabetes therapy. We used repeated-measures Cox proportional hazards regression to calculate hazard ratios (HRs) and 95% CIs for associations between potential predictors and incidence of fragility fracture.
Glycemic Control, Diabetic Complications, and Risk of Dementia in Patients With Diabetes: Results From a Large U.K. Cohort Study
Bang Zheng, Bowen Su, Geraint Price, Ioanna Tzoulaki, Sara Ahmadi-Abhari and Lefkos Middleton
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1556-1563.
OBJECTIVE Type 2 diabetes is an established risk factor for dementia. However, the roles of glycemic control and diabetic complications in the development of dementia have been less well substantiated. This large-scale cohort study aims to examine associations of longitudinal HbA1c levels and diabetic complications with the risk of dementia incidence among patients with type 2 diabetes.
Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
Anna R. Kahkoska, Trine Julie Abrahamsen, G. Caleb Alexander, Tellen D. Bennett, Christopher G. Chute, Melissa A. Haendel, Klara R. Klein, Hemalkumar Mehta, Joshua D. Miller, Richard A. Moffitt, Til Stürmer, Kajsa Kvist, John B. Buse and N3C Consortium
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1564-1572.
OBJECTIVE To determine the respective associations of premorbid glucagon-like peptide-1 receptor agonist (GLP1-RA) and sodium–glucose cotransporter 2 inhibitor (SGLT2i) use, compared with premorbid dipeptidyl peptidase 4 inhibitor (DPP4i) use, with severity of outcomes in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Increase in Prevalence of Diabetic Ketoacidosis at Diagnosis Among Youth With Type 1 Diabetes: The SEARCH for Diabetes in Youth Study
Elizabeth T. Jensen, Jeanette M. Stafford, Sharon Saydah, Ralph B. D’Agostino, Lawrence M. Dolan, Jean M. Lawrence, Santica Marcovina, Elizabeth J. Mayer-Davis, Catherine Pihoker, Arleta Rewers and Dana Dabelea
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1573-1578.
OBJECTIVE We previously reported a high (?30%) but stable prevalence of diabetic ketoacidosis (DKA) at youth-onset diagnosis of type 1 diabetes (2002 and 2010). Given the changing demographics of youth-onset type 1 diabetes, we sought to evaluate temporal trends in the prevalence of DKA at diagnosis of type 1 diabetes from 2010 to 2016 among youth <20 years of age and evaluate whether any change observed was associated with changes in sociodemographic distribution of those recently diagnosed.
Increased Incidence of Pediatric Type 1 Diabetes With Novel Association With Coxsackievirus A Species in Young Children but Declined Incidence in Adolescents in Taiwan
Wei-Liang Shih, Yi-Ching Tung, Luan-Yin Chang, Chi-Tai Fang and Wen-Yu Tsai
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1579-1585.
OBJECTIVE Type 1 diabetes (T1D) has been linked to enterovirus infection in small population-based epidemiological studies. We investigated the secular relationship of T1D incidence with enterovirus infection and enterovirus species using nationwide population-based analysis.
Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
Harpreet S. Bajaj, Richard M. Bergenstal, Andreas Christoffersen, Melanie J. Davies, Amoolya Gowda, Joakim Isendahl, Ildiko Lingvay, Peter A. Senior, Robert J. Silver, Roberto Trevisan and Julio Rosenstock
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1586-1594.
OBJECTIVE Insulin icodec (icodec) is a novel once-weekly basal insulin analog. This trial investigated two approaches for switching to icodec versus once-daily insulin glargine 100 units/mL (IGlar U100) in people with type 2 diabetes receiving daily basal insulin and one or more oral glucose-lowering medications.
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
Ildiko Lingvay, John B. Buse, Edward Franek, Melissa V. Hansen, Mette M. Koefoed, Chantal Mathieu, Jeremy Pettus, Karolina Stachlewska and Julio Rosenstock
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1595-1603.
OBJECTIVE Insulin icodec is a novel once-weekly basal insulin analog. This trial investigated the efficacy and safety of icodec using different once-weekly titration algorithms.
Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial
Johnny Ludvigsson, Zdenek Sumnik, Terezie Pelikanova, Lia Nattero Chavez, Elena Lundberg, Itxaso Rica, Maria A. Mart?nez-Brocca, Marisol Ruiz de Adana, Jeanette Wahlberg, Anastasia Katsarou, Ragnar Hanas, Cristina Hernandez, Maria Clemente Le?n, Ana G?mez-Gila, Marcus Lind, Marta Ferrer Lozano, Theo Sas, Ulf Samuelsson, Stepanka Pruhova, Fabricia Dietrich, Sara Puente Marin, Anders Nordlund, Ulf Hannelius and Rosaura Casas
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1604-1612.
OBJECTIVE To evaluate the efficacy of aluminum-formulated intralymphatic glutamic acid decarboxylase (GAD-alum) therapy combined with vitamin D supplementation in preserving endogenous insulin secretion in all patients with type 1 diabetes (T1D) or in a genetically prespecified subgroup.
Effect of Recombinant Human Parathyroid Hormone (1-84) on Resolution of Active Charcot Neuro-osteoarthropathy in Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study
Nina L. Petrova, Nicholas K. Donaldson, Maureen Bates, Wegin Tang, Timothy Jemmott, Victoria Morris, Tracy Dew, Lisa Meacock, David A. Elias, Cajetan F. Moniz and Michael E. Edmonds
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1613-1621.
OBJECTIVE Fractures in Charcot neuro-osteoarthropathy (CN) often fail to heal despite prolonged immobilization with below-knee casting. The aim of the study was to assess the efficacy of recombinant human parathyroid hormone (PTH) in reducing time to resolution of CN and healing of fractures.
The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure–Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial
Tu N. Nguyen, Katie Harris, Mark Woodward, John Chalmers, Mark Cooper, Pavel Hamet, Stephen Harrap, Simon Heller, Stephen MacMahon, Giuseppe Mancia, Michel Marre, Neil Poulter, Anthony Rogers, Bryan Williams, Sophia Zoungas, Clara K. Chow and Richard I. Lindley
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1622-1629.
OBJECTIVE To develop a frailty index (FI) and explore the relationship of frailty to subsequent adverse outcomes on the effectiveness and safety of more intensive control of both blood glucose and blood pressure (BP), among participants with type 2 diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes
Sue A. Brown, Gregory P. Forlenza, Bruce W. Bode, Jordan E. Pinsker, Carol J. Levy, Amy B. Criego, David W. Hansen, Irl B. Hirsch, Anders L. Carlson, Richard M. Bergenstal, Jennifer L. Sherr, Sanjeev N. Mehta, Lori M. Laffel, Viral N. Shah, Anuj Bhargava, Ruth S. Weinstock, Sarah A. MacLeish, Daniel J. DeSalvo, Thomas C. Jones, Grazia Aleppo, Bruce A. Buckingham and Trang T. Ly, for the Omnipod 5 Research Group
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1630-1640.
OBJECTIVE Advances in diabetes technology have transformed the treatment paradigm for type 1 diabetes, yet the burden of disease is significant. We report on a pivotal safety study of the first tubeless, on-body automated insulin delivery system with customizable glycemic targets.
Accuracy of Dexcom G6 Continuous Glucose Monitoring in Non–Critically Ill Hospitalized Patients With Diabetes
Georgia M. Davis, Elias K. Spanakis, Alexandra L. Migdal, Lakshmi G. Singh, Bonnie Albury, Maria Agustina Urrutia, K. Walkiria Zamudio-Coronado, William H. Scott, Rebecca Doerfler, Sergio Lizama, Medha Satyarengga, Kashif Munir, Rodolfo J. Galindo, Priyathama Vellanki, Saumeth Cardona, Francisco J. Pasquel, Limin Peng and Guillermo E. Umpierrez
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1641-1646.
OBJECTIVE Advances in continuous glucose monitoring (CGM) have transformed ambulatory diabetes management. Until recently, inpatient use of CGM has remained investigational, with limited data on its accuracy in the hospital setting.
Hemodialysis-Related Glycemic Disarray Proven by Continuous Glucose Monitoring; Glycemic Markers and Hypoglycemia
Akinori Hayashi, Naoya Shimizu, Agena Suzuki, Kenta Matoba, Akari Momozono, Tsuguto Masaki, Akifumi Ogawa, Ibuki Moriguchi, Koji Takano, Naoyuki Kobayashi and Masayoshi Shichiri
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1647-1656.
OBJECTIVE There is a high risk of asymptomatic hypoglycemia associated with hemodialysis (HD) using glucose-free dialysate; therefore, the inclusion of glucose in the dialysate is believed to prevent intradialytic hypoglycemia. However, the exact glycemic fluctuation profiles and frequency of asymptomatic hypoglycemia using dialysates containing >100 mg/dL glucose have not been determined.
High Burden of Subclinical and Cardiovascular Disease Risk in Adults With Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study
Yvonne Commodore-Mensah, Mariana Lazo, Olive Tang, Justin B. Echouffo-Tcheugui, Chiadi E. Ndumele, Vijay Nambi, Dan Wang, Christie Ballantyne and Elizabeth Selvin
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1657-1663.
OBJECTIVE It is controversial whether adults who are obese but “metabolically healthy” have cardiovascular disease (CVD) risk comparable with that of normal-weight adults. High-sensitivity cardiac troponin T (hs-cTnT), a biomarker of myocardial damage, is useful in characterizing subclinical CVD. We categorized obesity phenotypes and studied their associations with subclinical and clinical CVD and CVD subtypes, including heart failure (HF).
Long-term Predictions of Incident Coronary Artery Calcium to 85 Years of Age for Asymptomatic Individuals With and Without Type 2 Diabetes
Bart S. Ferket, M.G. Myriam Hunink, Umesh Masharani, Wendy Max, Joseph Yeboah and Kirsten E. Fleischmann
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1664-1671.
OBJECTIVE To examine the utility of repeated computed tomography (CT) coronary artery calcium (CAC) testing, we assessed risks of detectable CAC and its cardiovascular consequences in individuals with and without type 2 diabetes ages 45–85 years.
Dose-Dependent Associations of Dietary Glycemic Index, Glycemic Load, and Fiber With 3-Year Weight Loss Maintenance and Glycemic Status in a High-Risk Population: A Secondary Analysis of the Diabetes Prevention Study PREVIEW
Ruixin Zhu, Thomas M. Larsen, Mikael Fogelholm, Sally D. Poppitt, Pia S. Vestentoft, Marta P. Silvestre, Elli Jalo, Santiago Navas-Carretero, Maija Huttunen-Lenz, Moira A. Taylor, Gareth Stratton, Nils Swindell, Mathijs Drummen, Tanja C. Adam, Christian Ritz, Jouko Sundvall, Liisa M. Valsta, Roslyn Muirhead, Shannon Brodie, Teodora Handjieva-Darlenska, Svetoslav Handjiev, J. Alfredo Martinez, Ian A. Macdonald, Margriet S. Westerterp-Plantenga, Jennie Brand-Miller and Anne Raben
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1672-1681.
OBJECTIVE To examine longitudinal and dose-dependent associations of dietary glycemic index (GI), glycemic load (GL), and fiber with body weight and glycemic status during 3-year weight loss maintenance (WLM) in adults at high risk of type 2 diabetes.
Adipose Tissue Insulin Resistance Is Longitudinally Associated With Adipose Tissue Dysfunction, Circulating Lipids, and Dysglycemia: The PROMISE Cohort
Zhila Semnani-Azad, Philip W. Connelly, Richard P. Bazinet, Ravi Retnakaran, David J.A. Jenkins, Stewart B. Harris, Bernard Zinman and Anthony J. Hanley
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1682-1691.
OBJECTIVE To determine the association of adipose tissue insulin resistance with longitudinal changes in biomarkers of adipose tissue function, circulating lipids, and dysglycemia.
Differences in Body Composition Convey a Similar Risk of Type 2 Diabetes Among Different Ethnic Groups With Disparate Cardiometabolic Risk—The HELIUS Study
Marleen Zethof, Charlotte M. Mosterd, Didier Collard, Henrike Galenkamp, Charles Agyemang, Max Nieuwdorp, Daniël H. van Raalte and Bert-Jan H. van den Born
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1692-1698.
OBJECTIVE Studies have shown a disparate association between body composition and the risk of type 2 diabetes. We assessed whether associations between differences in body composition and type 2 diabetes vary among ethnic groups with disparate cardiometabolic risk.
Type 2 Diabetes, Metabolic Traits, and Risk of Heart Failure: A Mendelian Randomization Study
Ify R. Mordi, R. Thomas Lumbers, Colin N.A. Palmer, Ewan R. Pearson, Naveed Sattar, Michael V. Holmes and Chim C. Lang, on behalf of the HERMES Consortium
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1699-1705.
OBJECTIVE The aim of this study was to use Mendelian randomization (MR) techniques to estimate the causal relationships between genetic liability to type 2 diabetes (T2D), glycemic traits, and risk of heart failure (HF).
The Relationship Between Body Fat Distribution and Nonalcoholic Fatty Liver in Adults With Type 1 Diabetes
Erika B. Parente, Emma H. Dahlstr?m, Valma Harjutsalo, Jussi Inkeri, Stefan Mutter, Carol Forsblom, Niina Sandholm, Daniel Gordin and Per-Henrik Groop, on behalf of the FinnDiane Study Group
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1706-1713.
OBJECTIVE Obesity, which is associated with nonalcoholic fatty liver (NAFL), has increased among people with type 1 diabetes. Therefore, we explored the associations between body fat distribution and NAFL in this population.
Diabetic Polyneuropathy Early in Type 2 Diabetes Is Associated With Higher Incidence Rate of Cardiovascular Disease: Results From Two Danish Cohort Studies
Lasse Bjerg, Sia K. Nicolaisen, Diana H. Christensen, Jens S. Nielsen, Signe T. Andersen, Marit E. J?rgensen, Troels S. Jensen, Annelli Sandb?k, Henning Andersen, Henning Beck-Nielsen, Henrik T. S?rensen, Daniel R. Witte, Reimar W. Thomsen and Morten Charles
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1714-1721.
OBJECTIVE Symptoms indicative of diabetic polyneuropathy (DPN) early in type 2 diabetes may act as a marker for cardiovascular disease (CVD) and death.
Is the Consensual Threshold for Defining High Glucose Variability Implementable in Clinical Practice?
Jean-Baptiste Julla, Pauline Jacquemier, Guy Fagherazzi, Tiphaine Vidal-Trecan, Vanessa Juddoo, Asma Jaziri, Hanane Mersel, Nicolas Venteclef, Ronan Roussel, Pascale Massin, Aude Couturier, Jean-François Gautier and Jean-Pierre Riveline
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): 1722-1725.
OBJECTIVE Estimating glycemic variability (GV) through within-day coefficient of variation (%CVw) is recommended for patients with type 1 Diabetes (T1D). High GV (hGV) is defined as %CVw > 36%. However, continuous glucose monitoring (CGM) devices provide exclusively total CV (%CVT). We aimed to assess consequences of this disparity.
Factors Associated With Healing of Diabetes-Related Foot Ulcers: Observations From a Large Prospective Real-World Cohort
Yuqi Zhang, Susanna Cramb, Steven M. McPhail, Rosana Pacella, Jaap J. van Netten, Qinglu Cheng, Patrick H. Derhy, Ewan M. Kinnear and Peter A. Lazzarini, on behalf of the Diabetic Foot Working Group, Queensland Statewide Diabetes Clinical Network, Australia
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): e143-e145.
Increase in Diabetes Mortality Associated With COVID-19 Pandemic in the U.S.
Jinjun Ran, Shi Zhao, Lefei Han, Yang Ge, Marc K.C. Chong, Wangnan Cao and Shengzhi Sun
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): e146-e147.
User Engagement With the CamAPS FX Hybrid Closed-Loop App According to Age and User Characteristics
Natalie S. Chen, Charlotte K. Boughton, Sara Hartnell, Julia Fuchs, Janet M. Allen, Malgorzata E. Willinska, Ajay Thankamony, Carine de Beaufort, Fiona M. Campbell, Elke Fr?hlich-Reiterer, Sabine E. Hofer, Thomas M. Kapellen, Birgit Rami-Merhar, Atrayee Ghatak, Tabitha L. Randell, Rachel E. J. Besser, Daniela Elleri, Nicola Trevelyan, Louise Denvir, Nikki Davis, Eleanor Gurnell, Robert Lindsay, Damian Morris, Eleanor M. Scott, Lia Bally, Hood Thabit, Lalantha Leelarathna, Mark L. Evans, Helen R. Murphy, Julia K. Mader and Roman Hovorka, on behalf of AiDAPT, AP@home04, CLOuD, DAN05, DAN06, and KidsAP consortia
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): e148-e150.
Artificial Intelligence–Based Classification of Diabetic Peripheral Neuropathy From Corneal Confocal Microscopy Images
Tooba Salahouddin, Ioannis N. Petropoulos, Maryam Ferdousi, Georgios Ponirakis, Omar Asghar, Uazman Alam, Saadat Kamran, Ziyad R. Mahfoud, Nathan Efron, Rayaz A. Malik and Uvais A. Qidwai
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): e151-e153.
Comment on Ferrannini and Rosenstock. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646
Stavros Liatis
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): e154.
Response to Comment on Ferrannini and Rosenstock. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646
Ele Ferrannini and Julio Rosenstock
doi : 10.2337/dci21-0011
Diabetes Care 2021 Jul; 44 (7): e155.
